Taiho Files Domestic Application For TAS-102 Anti-Cancer Drug Formulation
This article was originally published in PharmAsia News
Executive Summary
Taiho Pharmaceuticals has applied for the approval of their anti-cancer drug TAS-102 (trifluridine and tipiracil hydrochloride) for the treatment of advance or recurrent colorectal cancer with unresectable cure, the company announced on Feb. 26.